Asia Pacific Molecular Diagnostics for Infectious Disease Market

The Asia Pacific molecular diagnostics for infectious disease market was valued at US$ 834.22 million in 2022 and is expected to reach US$ 2,360.34 million by 2030; it is estimated to grow at a CAGR of 13.9% from 2022 to 2030.

Advancements in Molecular Diagnostics Technologies Fuels the Asia Pacific Molecular Diagnostics for Infectious Disease Market

Genetic and genomic research has led to the development of molecular diagnostic techniques that focus on nucleic acid detection, which provide new methods for detecting infectious diseases with a fast turnaround time. A molecular diagnostic technique detects multiple pathogens and analyzes drug-resistant genes of pathogens and pathogen homology analysis, making it an increasingly important tool for the early diagnosis of infectious diseases. Molecular diagnostic techniques and platforms are used in all areas of anatomic and clinical pathologies. DNA or RNA sequences associated with disease, including single nucleotide polymorphism, deletions, rearrangements, and insertions, can be detected via molecular diagnostic tests. Conventionally, CT scans, hematological tests, and reverse transcription-PCR (RT-PCR) were used for testing. Due to growing infectious diseases, the need for rapid, precise testing platforms surged to overcome the disadvantages of conventional testing. Computed tomography (CT), a cost-intensive procedure that may not be available in all hospitals, fails to detect viral infections and other diseases in asymptomatic patients. RT-PCR was also time-consuming and could not detect a low viral load during the early stages of infection. Reverse transcription loop-mediated isothermal amplification (RT-LAMP), microarray-based detection, aptamer-based diagnosis, SHERLOCK, SHERLOCKv2, FET Biosensors, cell-based potentiometric diagnosis, and molecular imprinting technology are a few examples of novel molecular diagnostics techniques developed for infectious disease diagnosis. In the last few years, the FDA reports have indicated that molecular testing, antigen-dependent testing, and serological testing have been approved due to the advancements. Collaborative efforts by scientific communities in different countries to manage infectious diseases and reduce the extent of mortality have benefited the overall molecular tools and diagnosis landscape, which will likely create significant opportunities for the molecular diagnostics for infectious diseases market in the future.

Asia Pacific Molecular Diagnostics for Infectious Disease Market Overview

The molecular diagnostics for infectious disease market in Asia Pacific is subsegmented into Malaysia, Thailand, India, Singapore, the Philippines, Vietnam, Indonesia, China, Japan, Australia, South Korea, and the Rest of Asia Pacific. Rising geriatric population; increasing infectious diseases; growing research activities and technological advancements; and surging number of startups, biotechnology, and biopharmaceutical companies are the factors favoring the market progress in this region. Moreover, the presence of associations or organizations enhancing the quality of care in infectious disease management contributes to the molecular diagnostics for infectious disease market growth. According to a blog published by ChinaTown Online, ~1 in 7 people from the age range of 15-49 has been infected with sexually transmitted diseases (STDs) in China. Chlamydia, gonorrhea, genital warts, and syphilis are the most common STDs. According to the WHO, ~370 million new cases of trichomoniasis, Neisseria gonorrhea (NG), Chlamydia trachomatis (CT), and syphilis infections, among others, were detected in China in 2020. ~35% of the new infections registered were CT, which is one of the world's most commonly reported sexually transmitted infections (STIs). According to the WHO, by the 27th week of 2023, ~4,250 people were tested positive for influenza and nearly 23,300 specimens were processed for detection of influenza virus. This created a demand for molecular diagnostic products and services in Malaysia. Data published in the Korean Journal of Internal Medicine mentions that the incidence of TB in South Korea was 39 cases per 100,000 people in 2020. Moreover, the proportion of newly diagnosed cases of TB in elderly patients aged over 65 years has increased considerably from 27.5% (in 2008) to 48.5% (2020). According to the World Health Organization, Indonesia recorded 200 cases of human infection with the avian influenza A (H5N1) virus in January 2020. Out of these, 168 cases were fatal and resulted in an 84% mortality rate (168/200), which is much higher than the global fatality rate of 53%. Molecular diagnostic tools such as polymerase chain reaction (PCR), sequencing, hybridization, and microarray are employed for the detection of these infectious diseases as they surface as rapid and sensitive approaches for screening, detection, and monitoring.

Asia Pacific Molecular Diagnostics for Infectious Disease Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Molecular Diagnostics for Infectious Disease Market Segmentation

The Asia Pacific molecular diagnostics for infectious disease market is segmented based on type, end user, application, disease type, infection type, and country.

Based on type, the Asia Pacific molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The laboratory testing segment held a larger Asia Pacific molecular diagnostics market for infectious disease market share in 2022.

The Asia Pacific molecular diagnostics for infectious disease market, by end user, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further bifurcated into human testing and vet testing. Similarly, laboratory testing is further bifurcated into human testing and vet testing. The human testing segment, by point-of-care testing, held a larger Asia Pacific molecular diagnostics market for infectious disease market share in 2022. Additionally, the human testing segment, by laboratory testing, held a larger Asia Pacific molecular diagnostics market for infectious disease market share in 2022.

Based on application, the Asia Pacific molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into detection of single pathogen, detection of two or more pathogens, evaluation of emerging novel infections, surveillance and early detection of biothreat agents and diseases-related biomarker, and antimicrobial resistance profiling. Similarly, laboratory testing is further categorized into patient stratification, drug regimen selection, toxicity avoidance, therapeutic monitoring, and detection of predisposition to disease. The detection of a single pathogen segment, by point-of-care testing, held the largest Asia Pacific molecular diagnostics for infectious disease market share in 2022. Additionally, the drug regimen selection segment, by laboratory testing, held the largest Asia Pacific molecular diagnostics for infectious disease market share in 2022.

Based on disease type, the Asia Pacific molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into sepsis (e.g. urogenital/lung/wound), prosthetic joint infection, endocarditis, STDs, mononucleosis, group A streptococcus, and others. Similarly, laboratory testing is further categorized into sepsis, prosthetic joint infection, endocarditis, STDs, chlamydia, gastrointestinal infection, tuberculosis, H1N1 virus, and others. The STDs segment, by point-of-care testing, held the largest Asia Pacific molecular diagnostics for infectious disease market share in 2022. Additionally, the STDs segment, by laboratory testing, held the largest Asia Pacific molecular diagnostics for infectious disease market share in 2022.

Based on infection type, the Asia Pacific molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The Point-of-care testing is further segmented into bacteria, viral, fungi, and others. Similarly, laboratory testing is further categorized into bacteria, viral, fungi, and others. The bacteria segment, by point-of-care testing, held the largest Asia Pacific molecular diagnostics for infectious disease market share in 2022. Additionally, the bacteria segment, by laboratory testing, held the largest Asia Pacific molecular diagnostics for infectious disease market share in 2022.

Based on country, the Asia Pacific molecular diagnostics for infectious disease market is categorized into Malaysia, India, Indonesia, China, Japan, South Korea, and the Rest of Asia Pacific. The Rest of Asia Pacific dominated the Asia Pacific molecular diagnostics for infectious disease market in 2022.

Abbott Laboratories, bioMerieux SA, Bruker Corp, Danaher Corp, DiaSorin SpA, F. Hoffmann-La Roche Ltd, Hologic Inc, Siemens Healthineers AG, and Thermo Fisher Scientific Inc are some of the leading companies operating in the Asia Pacific molecular diagnostics for infectious disease market.

Asia Pacific Molecular Diagnostics for Infectious Disease Strategic Insights

Strategic insights for the Asia Pacific Molecular Diagnostics for Infectious Disease provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Asia Pacific Molecular Diagnostics for Infectious Disease Report Scope

Asia Pacific Molecular Diagnostics for Infectious Disease Regional Insights

The geographic scope of the Asia Pacific Molecular Diagnostics for Infectious Disease refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.